Design and synthesis of selenazole-substituted ritonavir analogs
Authors:
- 1 August 2018
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 28 (14) , 2379-2381
Abstract
No abstract availableKeywords
Funding Information
- Strategic Priority Research Program of CAS (XDB14040201)
- MOST
- NNSFC
This publication has 32 references indexed in Scilit:
- Highly Potent HIV-1 Protease Inhibitors with Novel Tricyclic P2 Ligands: Design, Synthesis, and Protein–Ligand X-ray StudiesJournal of Medicinal Chemistry, 2013
- Pyridine-Substituted Desoxyritonavir Is a More Potent Inhibitor of Cytochrome P450 3A4 than RitonavirJournal of Medicinal Chemistry, 2013
- The Role of Selenium in Inflammation and Immunity: From Molecular Mechanisms to Therapeutic OpportunitiesAntioxidants & Redox Signaling, 2012
- Targeting HIV-1 innate immune responses therapeuticallyCurrent Opinion in HIV and AIDS, 2011
- Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel PharmacoenhancerACS Medicinal Chemistry Letters, 2010
- 1,2,3-Selenadiazole thioacetanilides: Synthesis and anti-HIV activity evaluationBioorganic & Medicinal Chemistry, 2009
- Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years laterNature Protocols, 2008
- Overview of boosted protease inhibitors in treatment-experienced HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2007
- Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2003
- Cellular factors as alternative targets for inhibition of HIV-11This review is based on the presentation originally made at the Ninth International Conference on Antiviral Research in Urabandai, Fukushima, Japan, May 19–24, 1996.1Antiviral Research, 1997